PRFX
PainReform Ltd.
0.9799
+0.0924+10.4%
Dec 16, 4:00:00 PM EST

Upcoming Earnings 

Report date
≈ -/-

Earnings Call Transcripts

This Quarter (Q4 '25)

No earnings call transcript available yet

Last Quarter (Q3 '25)

No earnings call transcript available

Key Stats

Market Cap
3.84M
P/E (TTM)
0.03
Basic EPS (TTM)
29.90
Dividend Yield
0%

About 

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

CEO
Dr. Ehud Geller Ph.D.
IPO
9/1/2020
Employees
2
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic